背景:中国已经在全国范围内实施了封锁,以从早期阶段遏制COVID-19。先前关于COVID-19对中国性传播疾病(STD)和血液传播病毒(BBV)引起的疾病的影响的研究得出了截然不同的结果,关于性病和BBV导致的死亡的研究很少。
目的:我们旨在阐明COVID-19封锁对病例的影响,死亡,性病和BBV的病死率。
方法:我们提取了每月艾滋病病例和死亡数据,淋病,梅毒,乙型肝炎,2015年1月至2021年12月,来自中国国家卫生健康委员会官方网站上的法定报告疾病报告数据库。我们使用描述性统计数据来总结病例数和死亡人数,并计算了实施全国封锁前后(2020年1月)的发病率和病死率。我们使用负二项分段回归模型来估计封锁对病例的直接和长期影响,死亡,和病例死亡率分别为2020年1月和2021年12月。
结果:艾滋病共14,800,330例,127,030例死亡,淋病,梅毒,乙型肝炎,丙型肝炎从2015年1月到2021年12月报告,封锁前发病率为149.11/100,000,封锁后发病率为151.41/100,000,锁定前的病死率为8.21/1000,锁定后的病死率为9.50/1000。在负二项模型中,艾滋病病例(-23.4%;0.766,0.626-0.939)和死亡(-23.9%;0.761,0.647-0.896),淋病病例(-34.3%;0.657,0.524-0.823),梅毒病例(-15.4%;0.846,0.763-0.937),乙型肝炎病例(-17.5%;0.825,0.726-0.937)和丙型肝炎病例(-19.6%;0.804,0.693-0.933)在2020年1月显示显着下降。淋病,梅毒和丙型肝炎在2020年1月的死亡人数或病死率上略有增加.到2021年12月,案件死亡,每种疾病的病死率均达到或保持低于预期水平.
结论:COVID-19封锁可能导致报告的艾滋病病例减少,淋病,梅毒,乙型肝炎,和丙型肝炎,更多报告的淋病死亡或病死率,梅毒和丙型肝炎在中国。
China implemented a nationwide lockdown to contain COVID-19 from an early stage. Previous studies of the impact of COVID-19 on sexually transmitted diseases (STDs) and diseases caused by blood-borne viruses (BBVs) in
China have yielded widely disparate results, and studies on deaths attributable to STDs and BBVs are scarce.
We aimed to elucidate the impact of COVID-19 lockdown on cases, deaths, and case-fatality ratios of STDs and BBVs.
We extracted monthly data on cases and deaths for AIDS, gonorrhea, syphilis, hepatitis B, and hepatitis C between January 2015 and December 2021 from the notifiable disease reporting database on the official website of the National Health Commission of
China. We used descriptive statistics to summarize the number of cases and deaths and calculated incidence and case-fatality ratios before and after the implementation of a nationwide lockdown (in January 2020). We used negative binominal segmented regression models to estimate the immediate and long-term impacts of lockdown on cases, deaths, and case-fatality ratios in January 2020 and December 2021, respectively.
A total of 14,800,330 cases of and 127,030 deaths from AIDS, gonorrhea, syphilis, hepatitis B, and hepatitis C were reported from January 2015 to December 2021, with an incidence of 149.11/100,000 before lockdown and 151.41/100,000 after lockdown and a case-fatality ratio of 8.21/1000 before lockdown and 9.50/1000 after lockdown. The negative binominal model showed significant decreases in January 2020 in AIDS cases (-23.4%; incidence rate ratio [IRR] 0.766, 95% CI 0.626-0.939) and deaths (-23.9%; IRR 0.761, 95% CI 0.647-0.896), gonorrhea cases (-34.3%; IRR 0.657, 95% CI 0.524-0.823), syphilis cases (-15.4%; IRR 0.846, 95% CI 0.763-0.937), hepatitis B cases (-17.5%; IRR 0.825, 95% CI 0.726-0.937), and hepatitis C cases (-19.6%; IRR 0.804, 95% CI 0.693-0.933). Gonorrhea, syphilis, and hepatitis C showed small increases in the number of deaths and case-fatality ratios in January 2020. By December 2021, the cases, deaths, and case-fatality ratios for each disease had either reached or remained below expected levels.
COVID-19 lockdown may have contributed to fewer reported cases of AIDS, gonorrhea, syphilis, hepatitis B, and hepatitis C and more reported deaths and case-fatality ratios of gonorrhea, syphilis, and hepatitis C in
China.